Biomarker Profiling by Nuclear Magnetic Resonance Spectroscopy for the Prediction of All-Cause Mortality: An Observational Study of 17,345 Persons

Summary

Background Early identification of ambulatory persons at high short-term risk of death could benefit targeted prevention. To identify biomarkers for all-cause mortality and enhance risk prediction, we conducted high-throughput profiling of blood specimens in two large population-based cohorts. Methods and Findings 106 candidate biomarkers were quantified by nuclear magnetic resonance spectroscopy of non-fasting plasma samples from a random subset of the Estonian Biobank (n = 9,842; age range 18–103 y; 508 deaths during a median of 5.4 y of follow-up). Biomarkers for all-cause mortality were examined using stepwise proportional hazards models. Significant biomarkers were validated and incremental predictive utility assessed in a population-based cohort from Finland (n = 7,503; 176 deaths during 5 y of follow-up). Four circulating biomarkers predicted the risk of all-cause mortality among participants from the Estonian Biobank after adjusting for conventional risk factors: alpha-1-acid glycoprotein (hazard ratio [HR] 1.67 per 1–standard deviation increment, 95% CI 1.53–1.82, p = 5×10−31), albumin (HR 0.70, 95% CI 0.65–0.76, p = 2×10−18), very-low-density lipoprotein particle size (HR 0.69, 95% CI 0.62–0.77, p = 3×10−12), and citrate (HR 1.33, 95% CI 1.21–1.45, p = 5×10−10). All four biomarkers were predictive of cardiovascular mortality, as well as death from cancer and other nonvascular diseases. One in five participants in the Estonian Biobank cohort with a biomarker summary score within the highest percentile died during the first year of follow-up, indicating prominent systemic reflections of frailty. The biomarker associations all replicated in the Finnish validation cohort. Including the four biomarkers in a risk prediction score improved risk assessment for 5-y mortality (increase in C-statistics 0.031, p = 0.01; continuous reclassification improvement 26.3%, p = 0.001). Conclusions Biomarker associations with cardiovascular, nonvascular, and cancer mortality suggest novel systemic connectivities across seemingly disparate morbidities. The biomarker profiling improved prediction of the short-term risk of death from all causes above established risk factors. Further investigations are needed to clarify the biological mechanisms and the utility of these biomarkers for guiding screening and prevention.

Related articles

• Why art? The role of arts in arts and health

  This article addresses the complex relationship between the arts and health, questioning the role of the arts in improving mental and physical well-being. It explores various theoretical constructs and empirical evidence while emphasizing the need for a coherent definition of art to understand its effects on health.

• Oncogenesis

  This article examines the role of p52-ZER6 in the metabolic reprogramming of tumor cells, highlighting its impact on the pentose phosphate pathway and tumor progression. The study provides insights into the biochemical processes involved and points to potential therapeutic targets for cancer treatment.

• From library to landscape: integrative annotation workflows for compound libraries in drug repurposing

  This article details the creation of two automated annotation workflows designed for the integration of chemical and bioactivity data from various public repositories to support drug repurposing projects.

• Comprehensive Hemodialysis and Nephrology Lecture

  This document is a detailed lecture series on hemodialysis and nephrology, discussing the fundamentals of dialysis, historical milestones, advanced modalities, and complications associated with the treatment, aiming to enhance understanding for medical trainees and professionals.

• ShiftScan: A tool for rapid analysis of high-throughput differential scanning fluorimetry data and compound prioritization

  This document presents ShiftScan, a standalone tool designed for the rapid analysis of differential scanning fluorimetry (DSF) data in drug discovery, enabling efficient filtering and prioritization of compounds based on thermal transition patterns. It aims to assist researchers in managing large datasets and improving the identification of potential drug candidates.